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Abstract
Background: Microglia are considered a major target for modulating neuroinflammatory and neurodegenerative
disease processes. Upon activation, microglia secrete inflammatory mediators that contribute to the resolution or to
further enhancement of damage in the central nervous system (CNS). Therefore, it is important to study the
intracellular pathways that are involved in the expression of the inflammatory mediators. Particularly, the role of the
phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and glycogen synthase kinase-3
(GSK-3) pathways in activated microglia is unclear. Thus, in the present study we investigated the role of Akt and
its downstream pathways, GSK-3 and mTOR, in lipopolysaccharide (LPS)-activated primary rat microglia by
pharmacological inhibition of these pathways in regard to the expression of cyclooxygenase (COX)-2 and
microsomal prostaglandin E synthase-1 (mPGES-1) and to the production of prostaglandin (PG) E2 and PGD2.
Findings: We show that inhibition of Akt by the Akt inhibitor X enhanced the production of PGE2 and PGD2
without affecting the expression of COX-2, mPGES-1, mPGES-2 and cytosolic prostaglandin E synthase (cPGES).
Moreover, inhibition of GSK-3 reduced the expression of both COX-2 and mPGES-1. In contrast, the mTOR inhibitor
rapamycin enhanced both COX-2 and mPGES-1 immunoreactivity and the release of PGE2 and PGD2. Interestingly,
NVP-BEZ235, a dual PI3K/mTOR inhibitor, enhanced COX-2 and reduced mPGES-1 immunoreactivity, albeit PGE2
and PGD2 levels were enhanced in LPS-stimulated microglia. However, this compound also increased PGE2 in non-
stimulated microglia.
Conclusion: Taken together, we demonstrate that blockade of mTOR and/or PI3K/Akt enhances prostanoid
production and that PI3K/Akt, GSK-3 and mTOR differently regulate the expression of mPGES-1 and COX-2 in
activated primary microglia. Therefore, these pathways are potential targets for the development of novel strategies
to modulate neuroinflammation.
Keywords: microglia, phosphatidylinositol 3-kinase, mammalian target of rapamycin, glycogen synthase kinase-3,
Akt, prostaglandins
Findings
Inflammation has been recognized not only as a mere
bystander in neurodegenerative diseases but also as a
factor driving disease progression. Microglia, the innate
phagocytic cells of the central nervous system (CNS),
constantly survey their microenvironment. Activated
microglia secrete inflammatory mediators, which could
contribute to neuronal damage. Different groups have
demonstrated that the inflammatory cyclooxygenase-2
(COX-2), inducible nitric oxide synthase (iNOS) and
cytokines, such as interleukin (IL)-1b, IL-6 and tumor
necrosis factor (TNF)-a, are associated with neurode-
generative diseases [1]. Thus, reduction of microglia
activation is an important target in the treatment of
neurodegenerative diseases. Therefore, much effort has
been made to identify intracellular pathways that are
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mediators. However, many intracellular pathways which
are involved in the production of inflammatory media-
tors by microglia are not well characterized. In particu-
lar, the role of the phosphatidylinositol 3-kinase (PI3K)
signal cascade in mediating neuroinflammatory pro-
cesses is poorly studied.
The PI3K pathway can be activated by different sti-
muli including LPS via the toll-like receptor 4/CD14
receptor complex in microglia. After activation, PI3K
phosphorylates phosphatidylinositol 4,5-bisphosphate to
generate phosphatidylinositol-3,4,5-trisphosphate. The
latter molecule binds to the pleckstrin homology
domain of one of the Akt (also known as protein kinase
B) isoforms and facilitates the phosphorylation of Akt1,
Akt2 or Akt3 at Thr
308/309/305 and Ser
273/474/472,r e s p e c -
tively, by the phosphatidylinositol-dependent kinases 1
and 2 [2]. The phosphorylation on the respective resi-
dues of Akt leads to further catalytic activity changes of
downstream targets, such as glycogen synthase kinase-3
(GSK-3) and mammalian target of rapamycin (mTOR)
[3,4].
Recently, we and others have demonstrated that PI3K
might play an important role in inflammation and
microglia activation. In particular, we have demon-
strated that COX-2 is up-regulated and microsomal
prostaglandin E synthase-1 (mPGES-1) is down-regu-
lated by the PI3K inhibitor LY294002 [5]. However,
downstream pathways of PI3K might also be important.
In order to investigate this issue, we utilized a pharma-
cological approach to further investigate the role of
PI3K and downstream pathways in the expression of
COX-2 and mPGES-1 by activated microglia.
Primary microglial cell cultures were established
from cerebral cortices of one-day neonatal Wistar rats
[6] as described in detail in our recent study [5]. The
purity of the microglial culture obtained in our experi-
ments was > 98% as determined by immunofluores-
cence and cytochemical analysis according to the
method developed by Gebicke-Haerter et al. (1989) [7].
To investigate the effect of the inhibition of down-
stream pathways of PI3K, the following compounds
were used: the PI3K inhibitors LY294002 and PI828, as
well as LY303511, the inactive analogue of LY294002
(all from Tocris, Ellisville, MO, or Calbiochem, Bad
Soden, Germany); Akt inhibitor X and mTOR inhibitor
rapamycin (both from Calbiochem, Bad Soden, Ger-
many); the dual PI3K/mTOR inhibitor NVP-BEZ235
(Axon Medchem BV, Groningen, The Netherlands);
the GSK-3 inhibitor SB216763 (Tocris, Ellisville, MO);
LPS (from Salmonella typhimurium,S i g m a - A l d r i c h ,
Taufkirchen, Germany). Stock solutions (5-10 mM)
were prepared in dimethyl sulfoxide (DMSO) and
stored at -20°C. Further dilutions were carried out in
DMSO and final concentration of DMSO for all con-
centrations of the drugs in culture medium was 0.1%.
All compounds, used at the given concentrations, did
not affect the viability of the cells as observed through
the MTT cell viability assay (data not shown).
To analyze COX-2 and mPGES-1 protein levels, cells
were incubated with the respective inhibitors for 30 min
followed by 48 h stimulation with LPS. In the analysis
of phosphorylation of p-70S6K, a downstream target of
mTOR, cells were incubated with the inhibitors for 30
min followed by 1 h stimulation with LPS. 30 to 50 μg
of protein from each sample was subjected to SDS-
PAGE on a 10-15% gel under reducing conditions. Pri-
mary antibodies were goat anti-COX-2 (M-19, Santa
Cruz, Heidelberg, Germany) diluted 1:500 in Tris-buf-
fered saline (TBS) containing 0.1% Tween 20 (Merck,
Darmstadt, Germany) and 1% bovine serum albumin
(BSA, Sigma-Aldrich), rabbit anti-mPGES-1 (Oxford
Biomedical Research, 1:1000), rabbit anti-phospho-
p70S6K (Cell Signaling Technology, Beverly, MA, USA,
1:1000), rabbit anti-actin (Sigma, 1:5000). Proteins were
detected with horseradish peroxidase (HRP)-coupled
rabbit anti-goat IgG (Santa Cruz, 1:100,000) or HRP-
coupled donkey anti-rabbit (GE Healthcare, Freiburg
Germany, 1:25,000) using chemiluminescence (ECL)
reagents (GE Healthcare).
To investigate the effect of Akt inhibitor X on cytoso-
lic prostaglandin E synthase (cPGES) and mPGES-2, we
performed real time PCR. Cells were pre-incubated with
Akt X inhibitor at different concentrations (0.1 - 5 μM)
and LPS (10 ng/ml) was subsequently added for total 24
h. RNA preparation was done by using RNAspin mini
RNA isolation kit (GE Healthcare) and for cDNA synth-
esis one microgram of total RNA was reverse tran-
scribed using M-MLV reverse transcriptase and random
hexamers (Promega, Mannheim, Germany). The synthe-
sized cDNA was the template for the real-time polymer-
ase chain reaction (PCR) amplification carried out by
the CFX96 real-time PCR detection system (Bio-Rad
Laboratories Inc.). Specific Probes and primers were
designed by using Universal probe library (Roche). Reac-
tion conditions were 5 min at 95°C, followed by 40
cycles of 10 s at 95°C, 30 s at 60°C, and 1 s at 72°C fol-
lowed by 10 s at 40°C. S12 served as an internal control
for sample normalization and the comparative cycle
threshold Ct method was used for data quantification as
described previously [8]. The following primer
sequences were used for mPGES-2: Forward 5’-
AGGAAGGTACCCATCCTGGT-3’,R e v e r s e5 ’-GAG-
GAGTCATTGAGCTGTTGC-3’; cPGES: Forward 5’-
TGTCTAATTTTGACCGTTTCTCTG-3’, Reverse 5’-
TCATCTGCTCCGTCTACTTCTG-3’; S12: Forward 5’-
GCGCTTAAATACCGTCATGC-3’, Reverse: 5’-
GACGCCGAATCTTGAACG-3’.
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were incubated with the respective inhibitors previously
for 30 min followed by 48 h stimulation with LPS.
Supernatants were harvested for the measurement of
the levels of PGD2 (Cayman Chemicals, Ann Arbor, MI,
USA) and PGE2 (AssayDesign, distributed by Biotrend,
Köln, Germany). All measurements were performed
according to the manufacturer’s instructions. The stan-
dards were used in the interval of 39-2500 pg/ml (sensi-
tivity of the assay was 36.2 pg/ml) for both
prostaglandins.
All experiments were carried out at least three times.
Original data were converted into % - values of LPS
control and mean ± S.E.M. were calculated. Values were
compared using t-test (two groups) or one-way ANOVA
with post-hoc Student-Newman-Keuls test (multiple
comparisons). The level of statistical significance was set
at a p value less than 0.05.
We have recently demonstrated that LY294002, a
PI3K inhibitor, reduces mPGES-1 and increases COX-2
expression, providing an interesting pattern of differen-
tial expression between these two enzymes [5]. To
further investigate the contribution of pathways down-
stream of PI3K, we inhibited Akt with Akt inhibitor X.
As shown in Figure 1, Akt inhibitor X slightly increased
COX-2 and reduced mPGES-1 protein levels induced by
LPS, although without reaching statistical difference
(Figure 1A-B). On the other hand, the Akt inhibitor X
increased significantly the production of PGE2 and
PGD2 in LPS-activated microglia (Figure 1C). To inves-
tigate whether the enhancement of PGE2 was due to an
increase in the expression of other prostaglandin
synthases, we investigated the effect of Akt inhibitor X
on mPGES-2 and cPGES. Interestingly, we found
mPGES-2 to be increased after 24 h stimulation with
LPS, albeit cPGES levels remained unchanged. However,
Akt inhibitor X did not affect the expression of both
enzymes (Figure 1D).
Since the involvement of Akt in the enhanced produc-
tion of prostanoids was suggested by using Akt inhibitor
X, we asked whether other downstream targets of PI3K/
Akt are affected. An important target of Akt is GSK-3.
Different studies have demonstrated that Akt inactivates
GSK-3 by phosphorylating a serine residue of this
Figure 1 Effect of Akt inhibitor X on COX-2 and mPGES-1 immunoreactivity and PGE2 and PGD2 release in primary LPS-stimulated rat
microglia. A: Immunoblot analysis of protein levels of COX-2, mPGES-1 and b-actin in LPS-activated microglia treated with Akt inhibitor X (0.1-5
μM). B: Quantitative densitometric analysis of COX-2 and mPGES-1 protein expression normalized to b-actin loading control. C: Effect of Akt
inhibitor X (0.1-5 μM) on PGE2 and PGD2 production after 48 h of LPS stimulation in rat primary microglia. D: Effect of Akt inhibitor X on mPGES-
2 and cPGES expression in primary LPS-stimulated rat microglia. *P < 0.05 with respect to LPS control.
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keeps GSK-3 in the active state, which might lead to
increased COX-2 levels. Thus, inhibition of GSK-3
could potentially decrease COX-2 expression. Our data
showed that the higher dose of the GSK-3 inhibitor
SB216763 (10 μM), significantly decreased COX-2 and
mPGES-1 immunoreactivity induced by LPS in primary
rat microglia (Figure 2A-B).
Thereafter, we asked whether mTOR inhibition alters
LPS-induced COX-2 and mPGES-1 protein synthesis.
Interestingly, rapamycin, a well-known mTOR inhibitor,
increased both COX-2 and mPGES-1 immunoreactivity
(Figure 3A-B). The production of PGE2 and PGD2 was
also strongly enhanced by rapamycin in LPS-stimulated
microglia (Figure 3C), but not in non-stimulated cells
(Figure 3D).
Considering the possible involvement of PI3K and
mTOR in the regulation of mPGES-1 and COX-2 in
microglia, we investigated the effect of NVP-BEZ235, a
dual PI3K/mTOR inhibitor. NVP-BEZ235 strongly
enhanced COX-2, but reduced mPGES-1 immunoreac-
tivity in activated microglia (Figure 4A-B). The synthesis
of PGE2 and PGD2 was also strongly enhanced (Figure
4C). We further investigated whether NVP-BEZ235
increases COX-2 and mPGES-1, as well as prostaglandin
synthesis, in absence of LPS. As shown in Figure 4D-E,
there was a trend to enhancement of COX-2 and
mPGES-1 expression. However, PGE2 synthesis was
increased in non-stimulated microglia (Figure 4F).
As expected, the PI3K inhibitors, LY294002 and
PI828, as well as rapamycin and NVP-BEZ235, reduced
the phosphorylation of p-70S6K, an indirect marker of
mTOR activation (Figure 4G). The PI3K inactive analo-
gue LY303511 did not change this parameter.
In the present study, we investigated the role of Akt
and downstream pathways in microglia activation with
special emphasis on the arachidonic acid cascade. We
provide new evidence that inhibition of these pathways
significantly influence microglia activation.
We have previously demonstrated that PI3K inhibition
reduced mPGES-1 and increased COX-2 synthesis in
activated microglia. Here we further investigated
whether inhibition of Akt and downstream pathways
contributes to the regulation of COX-2 and mPGES-1
in LPS-stimulated primary microglia. Although there
was a trend towards an increased expression of COX-2
and a reduction in the expression of mPGES-1 with the
exposure of the cells to Akt inhibitor X, no statistical
difference was observed (Figure 1A-B). We have also
observed that Akt inhibitor X did not change the
expression of mPGES-2 and cPGES. However, as can be
observed in Figure 1D, mPGES-2 is enhanced after 24 h
incubation of cells with LPS. Although most studies
indicate that mPGES-2 is a constitutive enzyme that is
not inducible, the finding of the present study is inter-
esting and is in accordance with some data that indi-
cates that mPGES-2 can be enhanced in some
conditions [10-12]. For example, Chaudhry et al. [10]
have shown that mPGES-2 is expressed in activated, but
not resting microglia of humans.
The highest dose of Akt inhibitor X significantly
increased PGE2 and PGD2, indicating that a little
enhancement in COX-2 expression is sufficient to
increase prostanoid production (Figure 1C). The
enhancement of PGE2 and PGD2 could be due to the
slight, though not significant, enhancement of COX-2
expression. However, there are some other possibilities
that could contribute to the enhancement of PGE2 and
PGD2. Akt inhibition could enhance the expression and
activity of PLA2 and COX-1, therefore enhancing the
available arachidonic acid and PGH2, which are sub-
strates for the synthesis of prostanoids. Moreover, it is
Figure 2 Effect of SB216763, a GSK-3 inhibitor, on mPGES-1
and COX-2 immunoreactivity in primary LPS-stimulated rat
microglia. A: Immunoblot analysis of protein levels of COX-2,
mPGES-1 and b-actin in LPS-activated microglia treated with
SB216763 (0.01-10 μM). B: Quantitative densitometric analysis of
mPGES-1 and COX-2 protein expression normalized to b-actin
loading control. *P < 0.05 with respect to LPS control.
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enzymatic activity of the COX-2 and the PGE and PGD
synthases.
We further investigated downstream pathways of Akt,
such as GSK-3. As expected, a selective GSK-3 inhibitor
reduced COX-2 and mPGES-1 immunoreactivity (Figure
2A-B). Although SB216763 has an IC50 in the nM
range, it needs to be emphasized that this determination
was performed with the isolated human enzyme [13], a
condition that differs from the studies that use whole
cells. In fact, different pharmacological effects have been
demonstrated in macrophages and microglia exposed to
this higher concentration [14-18].
Similar to our results, Takada et al. [19] have shown
that genetic deletion of GSK-3b reduces the activation
of NF-B and COX-2 expression induced by TNFa-sti-
mulated mouse embryonic fibroblasts. On the other
hand, previous work has shown that GSK-3b inhibition
results in COX-2 expression [20-22]. Moreover,
Yuskaitis and Jope [18] showed that GSK-3 inhibition by
the use of different GSK-3 inhibitors is not important
for COX-2 expression in LPS-stimulated BV-2 microglia.
This difference between the studies can be due to the
time of stimulation, the compounds used and the cell
types used, since we used primary rat microglia and the
authors of this independent study used the BV-2 cell
line. Although SB216763 has been shown to be selective
for GSK-3 over many other kinases [13], there is still
the possibility that other targets other than GSK-3 are
involved in COX-2 regulation. Some studies have
addressed the role of GSK-3 in COX-2 regulation, but
no data have been published concerning the role of
GSK-3 in mPGES-1 expression.
Besides GSK-3, another important target of Akt is
mTOR. Interestingly, here we demonstrate that COX-2
and mPGES-1 immunoreactivity, as well as PGE2 and
PGD2, were drastically increased by rapamycin, a selec-
tive inhibitor of mTOR, even at very low doses (Figure
Figure 3 Effect of rapamycin, a mTOR inhibitor, and NVP-BEZ235, a dual PI3K/mTOR inhibitor, on COX-2 and mPGES-1
immunoreactivity and PGE2 and PGD2 release in primary LPS-stimulated rat microglia. A: Immunoblot analysis of protein levels of COX-2,
mPGES-1 and b-actin in LPS-activated microglia treated with rapamycin (0.05-2.5 nM). B: Quantitative densitometric analysis of COX-2 and
mPGES-1 protein expression normalized to b-actin loading control. C: Effect of rapamycin (0.05-2.5 nM) on PGE2 and PGD2 production after 48 h
of LPS stimulation in rat primary microglia. D: Effect of incubation of rat microglia with rapamycin (0.05-2.5 nM) on PGE2 and PGD2 release in
absence of LPS. *P < 0.05 with respect to LPS control.
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that rapamycin increases the production of prostaglan-
dins. It has been shown that mTOR inhibitors reduced
NOS activity and iNOS expression induced by hypoxia
and a mixture of cytokines in BV-2 cells and primary
rat microglia, respectively [23,24]. However, Dello Russo
et al. [23] did not find any increment in the COX-2
expression with the association of a mixture of cytokines
and RAD001, another mTOR inhibitor. This discrepancy
between the studies might be due to the type of stimu-
l u sa n dad i f f e r e n c ei nt h ec h e m i c a ls t r u c t u r eo ft h e
drugs used.
Although rapamycin enhanced COX-2 and mPGES-1
protein levels, NVP-BEZ235, the dual PI3K/mTOR inhi-
bitor, strongly increased COX-2, but reduced mPGES-1
immunoreactivity induced by LPS in microglia (Figure
4A-B). In fact, we have already previously demonstrated
that the regulation of these two enzymes is not strictly
coupled [5]. Interestingly, PGE2 and PGD2 were
enhanced in LPS-stimulated. One hypothesis to explain
the enhancement of PGE2 with mPGES-1 reduction
might be that the remaining mPGES-1 expression,
together with cPGES and mPGES-2, which are
expressed in microglia, would be enough to produce the
high levels of PGE2. Moreover, the activity of the
enzymes could also be increased by the compound.
There are other studies demonstrating that PGE2
could be enhanced even with mPGES-1 reduction.
LY294002, a PI3K inhibitor, reduce mPGES-1 and
enhance COX-2 expression, although the production of
PGE2 and PGD2 is enhanced or not affected in LPS-sti-
mulated microglia [5]. Moreover, it has been demon-
strated that silencing mPGES-1 does not affect PGE2
production in IL-1b or TNFa-stimulated gingival
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Figure 4 Effect of NVP-BEZ235, a dual PI3K/mTOR inhibitor, on COX-2 and mPGES-1 immunoreactivity and PGE2 and PGD2 release in
primary LPS-stimulated rat microglia. A: Immunoblot analysis of protein levels of COX-2, mPGES-1 and b-actin in LPS-activated microglia
treated with NVP-BEZ235 (10-500 nM). B: Quantitative densitometric analysis of COX-2 and mPGES-1 protein expression normalized to b-actin
loading control. C: Effect of NVP-BEZ235 (10-500 nM) on PGE2 and PGD2 production after 48 h of LPS stimulation in rat primary microglia. D:
Effect of incubation of rat microglia with NVP-BEZ235 (10-500 nM) on COX-2 and mPGES-1 in absence of LPS. E: Quantitative densitometric
analysis of COX-2 and mPGES-1 protein expression normalized to b-actin loading control. For COX-2, there is a trend toward statistical
significance (P = 0.0675). F: Effect of incubation of rat microglia with NVP-BEZ235 (10-500 nM) on PGE2 release in absence of LPS. G: Effect of
PI3K inhibitors (LY294002 and PI828), LY303511 (inactive analogue of PI3K inhibitor), rapamycin (mTOR inhibitor) and NVP-BEZ235 (PI3K/mTOR
dual inhibitor) on p70S6K phosphorylation. *P < 0.05 with respect to LPS control.
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MK-886, an inhibitor of 5-lipoxygenase-activating pro-
tein, reduced mPGES-1 and increased COX-2 expres-
sion, but did not affect PGE2 synthesis. In fact, different
data suggest that COX-2 might the rate-limiting enzyme
in the synthesis of PGE2 [26-28].
Importantly, NVP-BEZ235 per se is able to increase
PGE2 in non-stimulated cells. This result suggests that
the dual PI3K/mTOR inhibitor might differently regu-
late the expression of inflammatory mediators in differ-
ent conditions, since it reduces mPGES-1 induced by
LPS and also upregulates this enzyme in non-stimulated
conditions. That the increase in PGE2 mediated by
NVP-BEZ235 is higher in non-stimulated in comparison
to stimulated microglia is probably due to the fact that
mPGES-1 is reduced in activated cells and increased in
non-activated cells. Taken together, we provide evidence
that the blockade of mTOR and/or PI3K/Akt enhances
prostanoid production by microglia.
The results with rapamycin and NVP-BEZ235 repre-
sent important findings, since rapamycin is a commer-
cially available drug used to prevent rejection of
transplanted kidney and NVP-BEZ235 was recently
identified [29] and is an orally bioavailable drug which
is currently studied in clinical trials for advanced solid
tumor patients. To date, only a few studies have demon-
strated the effects of NVP-BEZ235 in non-tumor cells.
Here we demonstrate that microglia may also be
affected by a double PI3K/mTOR inhibition by modify-
ing the production of inflammatory mediators in neu-
roinflammatory conditions. Considering that the
arachidonic acid cascade products might have important
roles in resolution and/or progression of neuroinflam-
mation, the effects of these compounds should be inves-
tigated in vivo.
In conclusion, we provide novel evidence that Akt,
GSK-3 and mTOR are important intracellular regulators
of microglia activation. Our data provide significant
information regarding the regulation of COX-2 and
mPGES-1 via the Akt/mTOR and Akt/GSK-3 pathways,
and suggest that interfering with these signalling cas-
cades using pharmacological inhibitors could modulate
the activation state of microglial cells during
neuroinflammation.
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